Detalhe da pesquisa
1.
Real-World Adherence to OnabotulinumtoxinA Treatment for Spasticity: Insights From the ASPIRE Study.
Arch Phys Med Rehabil
; 102(11): 2172-2184.e6, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34245684
2.
Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity.
PM R
; 13(10): 1079-1093, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33151636
3.
High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study.
Toxicon X
; 7: 100040, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32875289
4.
Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE Study.
PM R
; 12(11): 1120-1133, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31953896
5.
Adult Spasticity International Registry Study: methodology and baseline patient, healthcare provider, and caregiver characteristics.
J Rehabil Med
; 49(8): 659-666, 2017 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28805237
6.
Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis.
J Manag Care Pharm
; 18(9): 1-17, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23206263
7.
The "liberation procedure" for multiple sclerosis: sacrificing science at the altar of consumer demand.
J Am Coll Radiol
; 9(5): 305-8, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22554624